Wave Life Sciences Reports Q2 2026 Results: $490.6M Cash, Pipeline Advances in Obesity and AATD
WVE is trading near its 52-week low of $5.02 (9.8% above the low).
Summary
Wave Life Sciences posted Q2 2026 results with $490.6M in cash and a net loss of $69.4M. Key pipeline updates include the start of Phase 2a dosing for obesity drug WVE-007, an upcoming FDA meeting on accelerated approval for WVE-006, and a planned CTA for WVE-008.
Key Events · Earnings and Guidance · WVE
-
Q2 2026 Financial Results
Net loss of $69.4M on revenue of $2.3M; R&D expenses rose to $51.3M and G&A to $24.8M. Cash, equivalents, and marketable securities totaled $490.6M as of June 30, 2026, with expected runway into Q3 2028.
-
WVE-007 Phase 2a Dosing Underway
Dosing has begun in the Phase 2a multidose portion of the INLIGHT trial for WVE-007 in individuals with obesity (BMI 35-50 kg/m²). The trial will also inform potential in MASH, type 2 diabetes, and other cardiometabolic diseases.
-
FDA Meeting on WVE-006 Accelerated Approval
An FDA meeting is scheduled for end of summer 2026 to discuss a potential accelerated approval pathway for WVE-006 in AATD, following positive RestorAATion-2 data showing MZ-like phenotype restoration.
-
WVE-008 CTA Filing on Track
A Clinical Trial Application for WVE-008, targeting PNPLA3 I148M liver disease, is expected in the second half of 2026, supported by preclinical editing and liver fat reduction data.
Analysis · WVE · Life Sciences
Wave Life Sciences reported Q2 2026 financials with a net loss of $69.4 million and cash of $490.6 million, providing runway into Q3 2028. The update includes meaningful pipeline progress: dosing is underway in the Phase 2a INLIGHT trial for obesity candidate WVE-007, an FDA meeting is scheduled for end of summer 2026 to discuss accelerated approval for WVE-006 in AATD, and a CTA filing for WVE-008 is on track for 2H 2026. These milestones, combined with the cash position, reduce near-term financing risk and keep the company on track for multiple catalysts in the coming quarters.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1498 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, WVE was trading at $5.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $5.02 to $21.73. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.